Wei and colleagues (102) demonstrate that NDRG2 expression promotes sensitivity to the drug, adriamycin, in breast cancer cells by inhibiting proliferation in a p53-dependent manner (102). This evidence concerns the gene NDRG2 and breast carcinoma.